Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
the liquid may remain clear
39,95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Adler V, Yin Z, Fuchs SY, Benerza M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ and Ronai Z
Where infiltration involves harmless fluids leaking into tissue, extravasation involves vesicant agents, medications that cause direct tissue damage when they escape the vein